Press Releases 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 Eagle Pharmaceuticals Provides Business Update and Reiterates 2023 Guidance 6/15/23 Eagle Pharmaceuticals Receives FDA Qualified Infectious Disease Product (QIDP) and Fast-Track Designation for CAL02, Providing Five-Year Exclusivity Extension 6/14/23 Eagle Pharmaceuticals Announces Acceptance of Two Abstracts at the Society for Academic Emergency Medicine (SAEM) Annual Meeting 5/11/23 Eagle Pharmaceuticals Reports First Quarter 2023 Results 5/9/23 Eagle Pharmaceuticals Granted Unique J-Code for Byfavo®¹ (remimazolam for injection) from CMS 5/1/23 Eagle Pharmaceuticals to Host First Quarter 2023 Financial Results on May 9, 2023 4/27/23 Eagle Pharmaceuticals Reaches Settlement Agreement with Dr. Reddy’s Laboratories Inc. and Dr. Reddy’s Laboratories Ltd. Related to BENDEKA® (bendamustine hydrochloride) 4/5/23 Eagle Pharmaceuticals Reports Fourth Quarter and Full Year 2022 Results 3/13/23 Eagle Pharmaceuticals to Present at the Barclays Global Healthcare Conference 3/9/23 Eagle Pharmaceuticals to Host Fourth Quarter and Full Year 2022 Financial Results on March 13, 2023 3/3/23 Pagination First page Previous page Page 1 Current page 2 Page 3 Next page Last page
